Wimmer Associates 1 LLC lessened its stake in Becton Dickinson and Co (NYSE:BDX) by 2.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,777 shares of the medical instruments supplier’s stock after selling 309 shares during the quarter. Becton Dickinson and makes up approximately 2.6% of Wimmer Associates 1 LLC’s portfolio, making the stock its 7th biggest holding. Wimmer Associates 1 LLC’s holdings in Becton Dickinson and were worth $3,074,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of BDX. CWM LLC increased its position in Becton Dickinson and by 390.6% in the second quarter. CWM LLC now owns 785 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 625 shares during the period. Alps Advisors Inc. increased its position in Becton Dickinson and by 35.3% in the second quarter. Alps Advisors Inc. now owns 1,307 shares of the medical instruments supplier’s stock worth $313,000 after buying an additional 341 shares during the period. Virginia Retirement Systems ET AL acquired a new stake in Becton Dickinson and in the second quarter worth $4,815,000. KBC Group NV increased its position in Becton Dickinson and by 38.2% in the second quarter. KBC Group NV now owns 77,091 shares of the medical instruments supplier’s stock worth $18,468,000 after buying an additional 21,319 shares during the period. Finally, State of Wisconsin Investment Board increased its position in Becton Dickinson and by 6.8% in the second quarter. State of Wisconsin Investment Board now owns 260,035 shares of the medical instruments supplier’s stock worth $62,294,000 after buying an additional 16,569 shares during the period. 85.19% of the stock is currently owned by institutional investors.

In related news, SVP Charles R. Bodner sold 2,080 shares of the firm’s stock in a transaction dated Friday, November 16th. The stock was sold at an average price of $245.83, for a total transaction of $511,326.40. Following the completion of the transaction, the senior vice president now owns 4,497 shares of the company’s stock, valued at $1,105,497.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP James W. Borzi sold 5,887 shares of the firm’s stock in a transaction dated Friday, November 30th. The shares were sold at an average price of $252.37, for a total value of $1,485,702.19. Following the transaction, the executive vice president now directly owns 6,013 shares of the company’s stock, valued at approximately $1,517,500.81. The disclosure for this sale can be found here. In the last three months, insiders sold 81,795 shares of company stock valued at $19,571,318. Company insiders own 1.00% of the company’s stock.

Several equities research analysts have weighed in on the company. Citigroup increased their target price on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Barclays set a $260.00 target price on Becton Dickinson and and gave the stock a “hold” rating in a research report on Thursday, November 8th. Piper Jaffray Companies dropped their target price on Becton Dickinson and to $250.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 6th. UBS Group assumed coverage on Becton Dickinson and in a research report on Tuesday, November 27th. They issued a “neutral” rating and a $260.00 target price on the stock. Finally, Morgan Stanley increased their price target on Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 4th. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $254.20.

Shares of NYSE:BDX traded down $7.64 on Wednesday, hitting $244.92. The company’s stock had a trading volume of 1,452,711 shares, compared to its average volume of 1,222,641. Becton Dickinson and Co has a 12 month low of $209.91 and a 12 month high of $265.87. The stock has a market cap of $67.80 billion, a price-to-earnings ratio of 22.25, a PEG ratio of 1.75 and a beta of 1.21. The company has a debt-to-equity ratio of 0.90, a quick ratio of 0.69 and a current ratio of 1.03.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.93. Becton Dickinson and had a return on equity of 13.88% and a net margin of 1.47%. The company had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter in the prior year, the business posted $2.40 earnings per share. The company’s revenue for the quarter was up 39.0% compared to the same quarter last year. On average, equities research analysts predict that Becton Dickinson and Co will post 12.1 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 31st. Stockholders of record on Monday, December 10th will be paid a $0.77 dividend. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend is Friday, December 7th. This represents a $3.08 annualized dividend and a dividend yield of 1.26%. Becton Dickinson and’s dividend payout ratio is presently 27.25%.

TRADEMARK VIOLATION NOTICE: This report was first posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/wimmer-associates-1-llc-has-3-07-million-position-in-becton-dickinson-and-co-bdx/2662608.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: How Does the Quiet Period Work?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.